Entacapone is an adjunctive medication used in the treatment of Parkinson's disease and must be administered in combination with levodopa/carbidopa.

I. Proper Dosage and Administration of Entacapone

1. Standard Dosage Regimen

(1) The recommended dose of entacapone is 200 mg (1 tablet) taken concurrently with each dose of levodopa/carbidopa.

(2) The maximum daily dose is 8 administrations, i.e., 1600 mg per day. Clinical experience with doses exceeding this limit is limited.

2. Administration Instructions

(1) May be taken with or without food: Food does not affect the absorption of entacapone; the timing of administration may be chosen according to personal preference.

(2) Must be taken with levodopa preparations: Entacapone has no antiparkinsonian effect when used alone and must be combined with levodopa/carbidopa.

3. Dosage Adjustment Principles

(1) Levodopa dose reduction: If the patient's daily levodopa dose is ≥ 800 mg, or if moderate-to-severe dyskinesia was present before treatment, a reduction in levodopa dosage is usually required. In clinical studies, the mean daily levodopa dose was reduced by approximately 25% in patients requiring dose adjustment.

(2) Individualized optimization: The physician will adjust the levodopa dose or dosing interval based on the patient's response.

4. Use in Special Populations

(1) Hepatic impairment: Use with caution. In patients with hepatic impairment, the AUC and Cmax of entacapone following a single dose are approximately twice those in healthy subjects.

(2) Renal impairment: No dose adjustment is required in patients with mild-to-moderate renal impairment.

(3) Pediatric use: Safety and efficacy have not been established; use is not recommended.

II. Precautions for Entacapone Use

1. Drug Interaction Warnings

(1) Non-selective MAO inhibitors: Concomitant use with non-selective monoamine oxidase inhibitors such as phenelzine and tranylcypromine is contraindicated, as it may lead to excessive inhibition of the catecholamine metabolic pathway.

(2) Selective MAO-B inhibitors: May be used concomitantly with selective MAO-B inhibitors such as selegiline.

(3) Drugs metabolized by COMT: Use caution when co-administering with isoproterenol, epinephrine, dopamine, dobutamine, etc., as this may result in tachycardia, arrhythmias, and excessive blood pressure fluctuations.

(4) Warfarin: Concomitant use may increase the International Normalized Ratio (INR) by an average of 13%. INR should be monitored at the initiation of therapy or with dose increases.

2. Important Safety Warnings

(1) Sudden daytime sleep episodes: Approximately 2% of patients experience sudden daytime sleep attacks, including falling asleep without prior warning. Avoid driving and operating hazardous machinery during treatment.

(2) Orthostatic hypotension: Manifested as dizziness, nausea, and syncope, particularly during the initial treatment phase. Change positions slowly.

(3) Impulse control disorders: Uncontrolled behaviors such as compulsive gambling, shopping, or hypersexuality may occur. Patients should notify their physician if such symptoms develop.

(4) Diarrhea and colitis: Persistent watery diarrhea accompanied by weight loss may indicate drug-induced microscopic colitis; discontinue treatment and undergo further evaluation.

3. Discontinuation Precautions

(1) Abrupt discontinuation is strictly prohibited. Rapid withdrawal or substantial dose reduction may cause severe worsening of Parkinsonian symptoms, including hyperthermia, muscle rigidity, and altered consciousness resembling neuroleptic malignant syndrome.

(2) If discontinuation is necessary, the dose should be tapered gradually under medical supervision.

4. Other Precautions

(1) Iron chelation: Entacapone chelates iron; serum iron levels should be monitored during long-term use.

(2) Melanoma risk: Patients with Parkinson's disease have a higher risk of melanoma than the general population. Regular skin examinations are recommended during treatment.

(3) Hepatotoxicity: Although rare cases of cholestatic hepatitis have been reported, routine monitoring of liver function is advisable.

III. Healthy Lifestyle Recommendations for Patients Taking Entacapone

1. Dietary Management

(1) Protein distribution: Levodopa absorption is affected by high-protein diets. It is recommended to distribute daily protein evenly across meals or adopt a "protein redistribution" strategy (low protein during the day, normal protein at dinner).

(2) Dietary fiber: Consume plenty of vegetables, fruits, and whole grains to prevent constipation (incidence: 6%).

(3) Adequate hydration: Drink 1500–2000 ml of water daily to dilute urine and reduce urethral irritation.

2. Exercise and Rehabilitation

(1) Regular exercise: Engage in at least 150 minutes of moderate-intensity aerobic exercise (e.g., brisk walking, swimming) per week, combined with strength training and flexibility exercises.

(2) Balance training: Tai Chi, yoga, etc., help improve balance and reduce fall risk.

(3) Speech therapy: If speech becomes slurred, seek guidance from a speech therapist.